Illumina (ILMN) is a publicly traded Healthcare sector company. As of July 5, 2026, ILMN trades at $188.68 with a market cap of $28.55B and a P/E ratio of 34.18. ILMN moved +2.56% today. Year to date, ILMN is +42.13%; over the trailing twelve months it is +88.04%. Its 52-week range spans $68.70 to $189.46. Analyst consensus is buy with an average price target of $151.92. Rallies surfaces ILMN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Illumina Shares Jump 4.58% After Partner’s Test Wins FDA Breakthrough Designation: Illumina partner SkylineDx secured FDA Breakthrough Device Designation for its Merlin CP-GEP prognostic test, potentially accelerating priority review and market entry by months. ILMN shares climbed 4.58% on the news, reflecting investor optimism about new high-margin sequencing-based diagnostic applications.
| Metric | Value |
|---|---|
| Price | $188.68 |
| Market Cap | $28.55B |
| P/E Ratio | 34.18 |
| EPS | $5.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $189.46 |
| 52-Week Low | $68.70 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.39B |
| Net Income | $853.00M |
| Gross Margin | 66.20% |
13 analysts cover ILMN: 0 strong buy, 7 buy, 3 hold, 3 sell, 0 strong sell. Consensus rating is buy. Average price target: $151.92.